{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:06:04Z","timestamp":1775106364742,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01689-y","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:29:00Z","timestamp":1773336540000},"page":"2133-2152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Holistic Value Assessment of Tirbanibulin for Actinic Keratosis: European Multi-Criteria Decision Analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Carola","family":"Berking","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Gambarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Moscarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6575-2679","authenticated-orcid":false,"given":"Julio","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15107","author":"D de Berker","year":"2017","unstructured":"de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017. https:\/\/doi.org\/10.1111\/bjd.15107.","journal-title":"Br J Dermatol"},{"key":"1689_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0070-9","author":"P Chetty","year":"2015","unstructured":"Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther. 2015. https:\/\/doi.org\/10.1007\/s13555-015-0070-9.","journal-title":"Dermatol Ther"},{"key":"1689_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1605787","author":"J Savary","year":"2019","unstructured":"Savary J, Tine MC, Weber AC, Dorey J. Management and clinical practice of multiple face and scalp actinic keratosis in France. J Market Access Health Policy. 2019. https:\/\/doi.org\/10.1080\/20016689.2019.1605787.","journal-title":"J Market Access Health Policy"},{"key":"1689_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2019.10.004","author":"CPH Reinehr","year":"2019","unstructured":"Reinehr CPH, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.abd.2019.10.004.","journal-title":"An Bras Dermatol"},{"key":"1689_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12530","author":"E Stockfleth","year":"2015","unstructured":"Stockfleth E, Peris K, Guillen C, Cerio R, Basset-Seguin N, Foley P, et\u00a0al. Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol. 2015. https:\/\/doi.org\/10.1111\/jdv.12530.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1689_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12420","author":"RN Werner","year":"2013","unstructured":"Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013. https:\/\/doi.org\/10.1111\/bjd.12420.","journal-title":"Br J Dermatol"},{"key":"1689_CR7","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3486","author":"G Guorgis","year":"2020","unstructured":"Guorgis G, Anderson CD, Lyth J, Falk M. Actinic keratosis diagnosis and increased risk of developing skin cancer: a 10-year cohort study of 17,651 patients in Sweden. Acta Derm Venereol. 2020. https:\/\/doi.org\/10.2340\/00015555-3486.","journal-title":"Acta Derm Venereol"},{"key":"1689_CR8","first-page":"98","volume":"31","author":"E Dika","year":"2023","unstructured":"Dika E, Lambertini M, Veronesi G, Misciali C, Milani M, Bergant-Suhodolcan A, et\u00a0al. Folliculotropism in actinic keratoses in patients not responding to treatments: a pilot study. Acta Dermatovenerol Croatica. 2023;31:98\u2013100.","journal-title":"Acta Dermatovenerol Croatica"},{"key":"1689_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19636","author":"G Pellacani","year":"2024","unstructured":"Pellacani G, Schlesinger T, Bhatia N, Berman B, Lebwohl M, Cohen JL, et\u00a0al. Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.19636.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1689_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.134","author":"SC Flohil","year":"2013","unstructured":"Flohil SC, Van Der Leest RJT, Dowlatshahi EA, Hofman A, De Vries E, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study. J Invest Dermatol. 2013. https:\/\/doi.org\/10.1038\/jid.2013.134.","journal-title":"J Invest Dermatol"},{"key":"1689_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad371","author":"CD George","year":"2024","unstructured":"George CD, Lee T, Hollestein LM, Asgari MM, Nijsten T. Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljad371.","journal-title":"Br J Dermatol"},{"key":"1689_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284","author":"VD Criscione","year":"2009","unstructured":"Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial. Cancer. 2009. https:\/\/doi.org\/10.1002\/cncr.24284.","journal-title":"Cancer"},{"key":"1689_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14151","author":"MT Fernandez Figueras","year":"2017","unstructured":"Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017. https:\/\/doi.org\/10.1111\/jdv.14151.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1689_CR14","unstructured":"Lucas R, Mcmichael T, Smith W, Armstrong B, Pr\u00fcss-\u00dcst\u00fcn A, Zeeb H, et\u00a0al. World Health Organization Public Health and the Environment, Geneva, 2006"},{"key":"1689_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0295-4","author":"GR Tennvall","year":"2015","unstructured":"Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, H\u00e6dersdal M. Health related quality of life in patients with actinic keratosis - An observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes. 2015. https:\/\/doi.org\/10.1186\/s12955-015-0295-4.","journal-title":"Health Qual Life Outcomes"},{"key":"1689_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13180","author":"RN Werner","year":"2015","unstructured":"Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et\u00a0al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015. https:\/\/doi.org\/10.1111\/jdv.13180.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1689_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14048","author":"MV Heppt","year":"2020","unstructured":"Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, et\u00a0al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma \u2013 Short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. JDDG J Dtsch Dermatol Ges. 2020. https:\/\/doi.org\/10.1111\/ddg.14048.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1689_CR18","unstructured":"Actinic keratosis: diagnosis and treatment [Internet]. [cited 2025 Jun 6]. Available from: https:\/\/www.aad.org\/public\/diseases\/skin-cancer\/actinic-keratosis-treatment"},{"key":"1689_CR19","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.14026","author":"G Hofbauer","year":"2014","unstructured":"Hofbauer G, Anliker M, Boehncke WH, Brand C, Braun R, Gaide O, et\u00a0al. Swiss clinical practice guidelines on field cancerization of the skin. Swiss Med Wkly. 2014. https:\/\/doi.org\/10.4414\/smw.2014.14026.","journal-title":"Swiss Med Wkly"},{"key":"1689_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811850","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, et\u00a0al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1811850.","journal-title":"N Engl J Med"},{"key":"1689_CR21","first-page":"S2","volume":"7","author":"JQ Del Rosso","year":"2014","unstructured":"Del Rosso JQ, Kircik L, Goldenberg G, Berman B. Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. J Clin Aesthetic Dermatol. 2014;7:S2\u201312.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"1689_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19897","author":"L Kandolf","year":"2024","unstructured":"Kandolf L, Peris K, Malvehy J, Mosterd K, Heppt MV, Fargnoli MC, et\u00a0al. European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes). J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.19897.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1689_CR23","unstructured":"EMA. Klisyri | European Medicines Agency (EMA) [Internet]. 2021 [cited 2025 Jun 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/klisyri"},{"key":"1689_CR24","unstructured":"FDA. Highlights of prescribing information-100 cm2. 2024 [cited 2025 Jun 19]; Available from: www.fda.gov\/medwatch."},{"key":"1689_CR25","unstructured":"FDA. Highlights of prescribing information-25 cm. 2020 [cited 2025 Jun 19]; Available from: www.fda.gov\/medwatch."},{"key":"1689_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00674-3","author":"L Del Regno","year":"2022","unstructured":"Del Regno L, Catapano S, Di Stefani A, Cappilli S, Peris K. A review of existing therapies for actinic keratosis: current status and future directions. Am J Clin Dermatol. 2022. https:\/\/doi.org\/10.1007\/s40257-022-00674-3.","journal-title":"Am J Clin Dermatol"},{"key":"1689_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.12.003","author":"P Thokala","year":"2016","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et\u00a0al. Multiple criteria decision analysis for health care decision making - An introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016. https:\/\/doi.org\/10.1016\/j.jval.2015.12.003.","journal-title":"Value Health"},{"key":"1689_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1360545","author":"JI Drake","year":"2017","unstructured":"Drake JI, de Hart JCT, Monle\u00f3n C, Toro W, Valentim J. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016. J Market Access Health Policy. 2017. https:\/\/doi.org\/10.1080\/20016689.2017.1360545.","journal-title":"J Market Access Health Policy"},{"key":"1689_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.12.016","author":"K Marsh","year":"2016","unstructured":"Marsh K, Ijzerman M, Thokala P, Baltussen R, Boysen M, Kal\u00f3 Z, et\u00a0al. Multiple criteria decision analysis for health care decision making - Emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016. https:\/\/doi.org\/10.1016\/j.jval.2015.12.016.","journal-title":"Value Health"},{"key":"1689_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0284-3","author":"N Zozaya","year":"2018","unstructured":"Zozaya N, Mart\u00ednez-Galdeano L, Alcal\u00e1 B, Armario-Hita JC, Carmona C, Carrascosa JM, et\u00a0al. Determining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysis. BioDrugs. 2018. https:\/\/doi.org\/10.1007\/s40259-018-0284-3.","journal-title":"BioDrugs"},{"key":"1689_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2063842","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, Delgado S\u00e1nchez O, et\u00a0al. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Rev Pharmacoecon Outcomes Res. 2022. https:\/\/doi.org\/10.1080\/14737167.2022.2063842.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1111\/jdv.19432","volume":"38","author":"JJ Pereyra-Rodr\u00edguez","year":"2024","unstructured":"Pereyra-Rodr\u00edguez JJ, Poveda JL, Rivero A, Serra-Baldrich E, Silvestre JF, Armario-Hita JC, et\u00a0al. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA). J Eur Acad Dermatol Venereol. 2024;38:e59\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1689_CR33","unstructured":"EVIDEM 10th Edition. Instructions for synthesizing evidence and perform quality assessment of studies. Data on file. 2017."},{"key":"1689_CR34","unstructured":"EVIDEM 10th Edition. Concept & definitions. Data on file. 2017."},{"key":"1689_CR35","unstructured":"EVIDEM 10th Edition. Adapt & pilot. Data on file. 2017."},{"key":"1689_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01431-6","author":"J Ride","year":"2024","unstructured":"Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A reporting checklist for discrete choice experiments in health: the DIRECT checklist. Pharmacoeconomics. 2024. https:\/\/doi.org\/10.1007\/s40273-024-01431-6.","journal-title":"Pharmacoeconomics"},{"key":"1689_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109350","author":"M Falip","year":"2023","unstructured":"Falip M, L\u00f3pez Gonz\u00e1lez FJ, Mart\u00edn-Herranz I, Merino-Boh\u00f3rquez V, Montoya J, Rey G\u00f3mez-Serranillos I, et\u00a0al. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective multi-criteria decision analysis (MCDA). Epilepsy Behav. 2023. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109350.","journal-title":"Epilepsy Behav"},{"key":"1689_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1829884","author":"K Ezzedine","year":"2020","unstructured":"Ezzedine K, Painchault C, Brignone M. Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome. J Market Access Health Policy. 2020. https:\/\/doi.org\/10.1080\/20016689.2020.1829884.","journal-title":"J Market Access Health Policy"},{"key":"1689_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0247-0","author":"T Skov","year":"2018","unstructured":"Skov T, Stockfleth E, Szeimies RM, Berman B. Efficacy endpoints in clinical trials in actinic keratosis. Dermatol Ther Heidelb. 2018. https:\/\/doi.org\/10.1007\/s13555-018-0247-0.","journal-title":"Dermatol Ther Heidelb"},{"key":"1689_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0145-2","author":"RM Szeimies","year":"2016","unstructured":"Szeimies RM, Atanasov P, Bissonnette R. Use of lesion response rate in actinic keratosis trials. Dermatol Ther Heidelb. 2016. https:\/\/doi.org\/10.1007\/s13555-016-0145-2.","journal-title":"Dermatol Ther Heidelb"},{"key":"1689_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1254328","author":"T Dirschka","year":"2017","unstructured":"Dirschka T, Gupta G, Micali G, Stockfleth E, Basset-S\u00e9guin N, Del Marmol V, et\u00a0al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017. https:\/\/doi.org\/10.1080\/09546634.2016.1254328.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01689-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:26Z","timestamp":1775101106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01689-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01689-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julio Sosa has no conflicts to declare. The remaining authors (Carola Berking, Rafael Botella, Andrea Carugno, Giovanna Gambarelli, Josep Malvehy, Elvira Moscarella, Arianna Petracca, Gregorio Romero, Eggert Stockfleth, and Jose Luis Trillo Mata) received honorarium fees from Almirall S.A. for participating in qualitative interviews conducted as part of this research. The honorarium was provided as compensation for experts\u2019 time and expertise and did not influence the content, analysis, or conclusions of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is a non-interventional expert MCDA workshop\u00a0with multidisciplinary professionals. It involves\u00a0no intervention on human subjects, no administration of medicinal products or devices, and\u00a0no collection of patient data; therefore, it falls\u00a0outside the scope of clinical trial\/device investigation requirements\u00a0and is\u00a0not human-subjects biomedical research.\u00a0This non-interventional, survey-based study was conducted in accordance with the principles of the Declaration of Helsinki. All participants (clinicians, payers, and patients) provided informed consent before participation. The study involved no clinical procedures or collection of identifiable personal data. All participants\u00a0signed a participation agreement (including data-processing terms) and informed consent, and the analysis dataset contains only\u00a0aggregated\/anonymized responses\u00a0(contact\/payment details are stored separately per the agreement and privacy notice). Given the absence of identifiable\/sensitive data in the analytical dataset and the safeguards in place,\u00a0formal IRB\/REC review is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}